BioTelemetry Company Profile (NASDAQ:BEAT)

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry logoBioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BEAT
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.01 billion
  • Outstanding Shares: 32,360,000
Average Prices:
  • 50 Day Moving Avg: $33.90
  • 200 Day Moving Avg: $32.26
  • 52 Week Range: $15.25 - $39.20
  • Trailing P/E Ratio: 20.87
  • Foreward P/E Ratio: 23.38
  • P/E Growth: 1.48
Sales & Book Value:
  • Annual Revenue: $211.19 million
  • Price / Sales: 4.77
  • Book Value: $5.11 per share
  • Price / Book: 6.09
  • EBITDA: $41.34 million
  • Net Margins: 21.03%
  • Return on Equity: 18.75%
  • Return on Assets: 12.70%
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 2.03%
  • Quick Ratio: 1.91%
  • Average Volume: 511,862 shs.
  • Beta: 0.68
  • Short Ratio: 5.72

Frequently Asked Questions for BioTelemetry (NASDAQ:BEAT)

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) posted its quarterly earnings results on Tuesday, August, 8th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.21 by $0.02. The firm had revenue of $58.10 million for the quarter, compared to analyst estimates of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The company's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share. View BioTelemetry's Earnings History.

Where is BioTelemetry's stock going? Where will BioTelemetry's stock price be in 2017?

6 brokerages have issued twelve-month price objectives for BioTelemetry's shares. Their predictions range from $40.00 to $50.00. On average, they anticipate BioTelemetry's share price to reach $45.75 in the next year. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Who owns BioTelemetry stock?

BioTelemetry's stock is owned by many different of institutional and retail investors. Top institutional investors include Curbstone Financial Management Corp (0.07%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Who bought BioTelemetry stock? Who is buying BioTelemetry stock?

BioTelemetry's stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. View Insider Buying and Selling for BioTelemetry.

How do I buy BioTelemetry stock?

Shares of BioTelemetry can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BioTelemetry stock can currently be purchased for approximately $31.10.

MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioTelemetry (NASDAQ:BEAT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $45.75 (47.11% upside)
Consensus Price Target History for BioTelemetry (NASDAQ:BEAT)
Price Target History for BioTelemetry (NASDAQ:BEAT)
Analysts' Ratings History for BioTelemetry (NASDAQ:BEAT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Off Wall StreetInitiated CoverageSellMediumView Rating Details
8/10/2017SidotiReiterated RatingBuy$42.00 -> $49.00LowView Rating Details
8/9/2017Dougherty & CoBoost Price TargetBuy$37.00 -> $40.00HighView Rating Details
7/19/2017Benchmark Co.Boost Price TargetBuy -> Buy$38.00 -> $44.00LowView Rating Details
7/14/2017Lake Street CapitalReiterated RatingBuy$35.00 -> $50.00HighView Rating Details
12/13/2016GabelliReiterated RatingBuyN/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for BioTelemetry (NASDAQ:BEAT)
Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)
Earnings History by Quarter for BioTelemetry (NASDAQ BEAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017$0.21$0.23$58.39 million$58.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.14$0.16$55.11 million$55.88 millionViewListenView Earnings Details
2/22/2017Q4 2016$0.18$0.23$53.75 million$53.96 millionViewListenView Earnings Details
11/2/2016Q316$0.18$0.21$52.92 million$53.10 millionViewN/AView Earnings Details
8/2/2016Q2$0.17$0.20$50.27 million$52.68 millionViewListenView Earnings Details
4/26/2016Q1$0.10$0.20$46.54 million$48.60 millionViewListenView Earnings Details
2/17/2016Q415$0.11$0.15$45.89 million$46.70 millionViewListenView Earnings Details
11/9/2015Q3$0.11$0.13$46.05 million$43.49 millionViewN/AView Earnings Details
8/6/2015Q2$0.09$0.12$45.75 million$44.81 millionViewListenView Earnings Details
5/6/2015Q115$0.02$0.06$43.80 million$43.40 millionViewListenView Earnings Details
2/19/2015Q414$0.06$0.05$43.40 million$43.70 millionViewListenView Earnings Details
10/30/2014Q214$0.01$0.06$42.00 million$43.00 millionViewListenView Earnings Details
7/31/2014Q114$0.01$0.02$40.95 million$42.70 millionViewListenView Earnings Details
5/6/2014Q413($0.02)($0.04)$38.40 million$37.16 millionViewListenView Earnings Details
2/26/2014Q313($0.04)$0.05$32.26 million$33.10 millionViewListenView Earnings Details
11/5/2013($0.05)($0.12)$32.79 million$31.90 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.02$27.50 million$32.10 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.09)$26.80 million$30.00 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.08)$26.49 million$27.00 millionViewN/AView Earnings Details
8/8/2012($0.04)($0.01)ViewN/AView Earnings Details
5/8/2012($0.12)($0.10)ViewN/AView Earnings Details
2/22/2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2011($0.09)($0.21)ViewN/AView Earnings Details
8/8/2011($0.06)($0.05)ViewN/AView Earnings Details
5/3/2011($0.15)($0.02)ViewN/AView Earnings Details
2/17/2011($0.16)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioTelemetry (NASDAQ:BEAT)
2017 EPS Consensus Estimate: $0.86
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.20$0.20$0.20
Q2 20171$0.20$0.20$0.20
Q3 20172$0.19$0.28$0.24
Q4 20171$0.22$0.22$0.22
(Data provided by Zacks Investment Research)


Dividend History for BioTelemetry (NASDAQ:BEAT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioTelemetry (NASDAQ:BEAT)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 77.67%
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Robert J. RubinDirectorSell15,000$28.14$422,100.00View SEC Filing  
3/20/2017Fred BroadwaySVPSell3,429$26.90$92,240.10View SEC Filing  
2/27/2017George HrenkoSVPSell126,043$25.95$3,270,815.85View SEC Filing  
2/21/2017Fred BroadwaySVPSell8,070$24.81$200,216.70View SEC Filing  
9/19/2016George HrenkoSVPSell1,061$18.50$19,628.50View SEC Filing  
9/13/2016Heather C GetzCFOSell5,866$18.23$106,937.18View SEC Filing  
9/13/2016Joseph H CapperInsiderSell26,847$18.23$489,420.81View SEC Filing  
9/13/2016Peter FerolaGeneral CounselSell4,352$18.23$79,336.96View SEC Filing  
9/9/2016Fred BroadwaySVPSell3,146$17.84$56,124.64View SEC Filing  
9/8/2016George HrenkoSVPSell3,491$18.06$63,047.46View SEC Filing  
9/8/2016Heather C GetzCFOSell2,979$18.10$53,919.90View SEC Filing  
9/8/2016Joseph H CapperInsiderSell13,632$18.10$246,739.20View SEC Filing  
9/8/2016Peter FerolaGeneral CounselSell2,210$18.10$40,001.00View SEC Filing  
9/7/2016Daniel WisniewskiSVPSell9,225$18.51$170,754.75View SEC Filing  
9/7/2016Heather C GetzCFOSell18,945$18.52$350,861.40View SEC Filing  
9/7/2016Joseph H CapperInsiderSell86,681$18.52$1,605,332.12View SEC Filing  
9/7/2016Peter FerolaGeneral CounselSell14,053$18.52$260,261.56View SEC Filing  
9/6/2016Fred BroadwaySVPSell4,662$18.28$85,221.36View SEC Filing  
9/6/2016Heather C GetzCFOSell6,686$18.29$122,286.94View SEC Filing  
9/6/2016Joseph H CapperCEOSell30,595$18.29$559,582.55View SEC Filing  
9/6/2016Peter FerolaGeneral CounselSell4,960$18.29$90,718.40View SEC Filing  
9/2/2016Fred BroadwaySVPSell4,466$18.75$83,737.50View SEC Filing  
9/2/2016Heather C GetzCFOSell6,547$18.75$122,756.25View SEC Filing  
9/2/2016Joseph H CapperCEOSell29,953$18.75$561,618.75View SEC Filing  
9/2/2016Peter FerolaGeneral CounselSell4,856$18.75$91,050.00View SEC Filing  
9/1/2016Fred BroadwaySVPSell7,525$19.25$144,856.25View SEC Filing  
9/1/2016Heather C GetzCFOSell10,408$18.59$193,484.72View SEC Filing  
9/1/2016Joseph H CapperInsiderSell47,622$18.59$885,292.98View SEC Filing  
9/1/2016Peter FerolaGeneral CounselSell7,722$18.59$143,551.98View SEC Filing  
8/30/2016Fred BroadwaySVPSell12,121$19.07$231,147.47View SEC Filing  
8/30/2016Heather C GetzCFOSell17,482$19.07$333,381.74View SEC Filing  
8/30/2016Joseph H CapperInsiderSell79,986$19.07$1,525,333.02View SEC Filing  
8/30/2016Peter FerolaGeneral CounselSell12,970$19.07$247,337.90View SEC Filing  
8/25/2016Fred BroadwaySVPSell5,877$19.16$112,603.32View SEC Filing  
8/25/2016Heather C GetzCFOSell8,477$19.16$162,419.32View SEC Filing  
8/25/2016Joseph H CapperInsiderSell38,785$19.16$743,120.60View SEC Filing  
8/25/2016Peter FerolaGeneral CounselSell6,289$19.16$120,497.24View SEC Filing  
8/24/2016George HrenkoSVPSell7,473$20.11$150,282.03View SEC Filing  
8/24/2016Heather C GetzCFOSell8,778$20.11$176,525.58View SEC Filing  
8/24/2016Joseph H CapperCEOSell40,160$20.11$807,617.60View SEC Filing  
8/24/2016Peter FerolaGeneral CounselSell6,512$20.11$130,956.32View SEC Filing  
8/23/2016George HrenkoSVPSell3,165$20.67$65,420.55View SEC Filing  
8/23/2016Heather C GetzCFOSell3,717$20.67$76,830.39View SEC Filing  
8/23/2016Joseph H CapperCEOSell17,008$20.67$351,555.36View SEC Filing  
8/23/2016Peter FerolaGeneral CounselSell2,758$20.67$57,007.86View SEC Filing  
8/22/2016George HrenkoSVPSell4,149$20.85$86,506.65View SEC Filing  
8/22/2016Heather C GetzCFOSell4,874$20.85$101,622.90View SEC Filing  
8/22/2016Joseph H CapperCEOSell22,298$20.85$464,913.30View SEC Filing  
8/22/2016Peter FerolaGeneral CounselSell3,616$20.85$75,393.60View SEC Filing  
8/19/2016Daniel WisniewskiSVPSell9,025$20.96$189,164.00View SEC Filing  
8/19/2016Heather C GetzCFOSell9,026$20.96$189,184.96View SEC Filing  
8/19/2016Joseph H CapperInsiderSell9,049$20.96$189,667.04View SEC Filing  
8/19/2016Peter FerolaGeneral CounselSell9,035$20.96$189,373.60View SEC Filing  
5/9/2014Ronald AhrensDirectorBuy6,000$7.37$44,220.00View SEC Filing  
11/12/2013Ronald AhrensDirectorBuy5,000$11.73$58,650.00View SEC Filing  
11/12/2012Ronald A AhrensDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/5/2012Joseph H CapperCEOBuy23,540$2.25$52,965.00View SEC Filing  
8/31/2012Joseph H CapperCEOBuy2,600$2.28$5,928.00View SEC Filing  
8/29/2012Joseph H CapperCEOBuy10,800$2.30$24,840.00View SEC Filing  
8/28/2012Joseph H CapperCEOBuy1,300$2.19$2,847.00View SEC Filing  
8/27/2012Joseph H CapperCEOBuy1,600$2.12$3,392.00View SEC Filing  
8/23/2012Joseph H CapperCEOBuy9,600$2.08$19,968.00View SEC Filing  
8/20/2012Joseph H CapperCEOBuy14,160$1.97$27,895.20View SEC Filing  
8/17/2012Joseph H CapperCEOBuy9,800$2.10$20,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioTelemetry (NASDAQ:BEAT)
Latest Headlines for BioTelemetry (NASDAQ:BEAT)
DateHeadline logoBioTelemetry, Inc. (BEAT) Receives Consensus Rating of "Buy" from Analysts - October 11 at 4:42 PM logoStocks Under Scanner in the Medical Research Space -- Organovo, BioTelemetry, Bruker, and PerkinElmer - October 10 at 5:42 PM logoHow Did BioTelemetry Inc’s (BEAT) 39.58% ROE Fare Against The Industry? - October 6 at 4:43 PM logoBioTelemetry, Royal Gold, Microsoft and Amazon highlighted as Zacks Bull and Bear of the Day - October 6 at 4:43 PM logoBull of the Day: BioTelemetry (BEAT) - October 6 at 8:21 AM logoBioTelemetry: Cramer's Top Takeaways - October 4 at 1:20 PM logoHere's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now - October 2 at 11:54 AM logoPAREXEL's Acquisition by Pamplona Approved by Shareholders - October 2 at 11:53 AM logoCramer reviews the bull and bear cases for medical device... - October 2 at 11:53 AM logoBiotelemetry: King Of A Growing Market - Seeking Alpha - September 28 at 12:39 AM logoHere's Why You Should Bet on BioTelemetry (BEAT) Stock Now - September 21 at 4:14 PM logoXHS's Holdings Imply 15% Gain Potential - September 21 at 11:48 AM logo5 Momentum Stocks Powered by Driehaus Strategy - September 21 at 11:48 AM logoHere's Why You Should Bet on BioTelemetry (BEAT) Stock Now - September 21 at 11:48 AM logoETFs with exposure to BioTelemetry, Inc. : September 19, 2017 - September 19 at 9:30 PM logoBioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : September 19, 2017 - September 19 at 9:30 PM logoBioTelemetry Enters Oversold Territory (BEAT) - September 18 at 4:49 PM logoBioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : September 18, 2017 - September 18 at 4:49 PM logoBioTelemetry, Inc. (BEAT) Receives Average Rating of "Buy" from Analysts - September 16 at 4:54 PM logoNotable Friday Option Activity: LOW, GRA, BEAT - Nasdaq - September 15 at 9:54 PM logoDoes BioTelemetry Inc’s (BEAT) PE Ratio Warrant A Buy? - September 15 at 4:50 PM logoBioTelemetry, Inc. (BEAT) Now Covered by Analysts at Off Wall Street - September 15 at 11:48 AM logoCan BioTelemetry (BEAT) Run Higher on Strong Earnings Estimate Revisions? - August 30 at 5:44 PM logoSignal Genetics (MGEN) vs. BioTelemetry (BEAT) Critical Contrast - August 30 at 12:18 PM logoShort Interest in BioTelemetry, Inc. (BEAT) Drops By 33.7% - August 29 at 1:06 AM logoWhy Biotelemetry (BEAT) Could Be an Impressive Growth Stock - Nasdaq - August 23 at 9:37 PM logoETFs with exposure to BioTelemetry, Inc. : August 21, 2017 - August 23 at 4:37 PM logoWhy Biotelemetry (BEAT) Could Be an Impressive Growth Stock - August 23 at 4:37 PM logoBioTelemetry, Inc. (BEAT) Receives Consensus Recommendation of "Buy" from Analysts - August 22 at 4:36 PM logoTrump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks - Nasdaq - August 22 at 2:29 AM logoHere's Why Investors Should Buy BioTelemetry (BEAT) Now - Nasdaq - August 22 at 2:29 AM logoBioTelemetry (BEAT) vs. Signal Genetics (MGEN) Financial Review - August 22 at 12:18 AM logoHere's Why Investors Should Buy BioTelemetry (BEAT) Now - August 21 at 4:27 PM logoTrump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks - August 21 at 4:27 PM logoHere's Why Investors Should Buy BioTelemetry (BEAT) Now - August 21 at 4:27 PM logoBioTelemetry, Inc. (BEAT) Expected to Earn FY2017 Earnings of $1.00 Per Share - August 21 at 5:34 AM logoHead-To-Head Survey: BioTelemetry (BEAT) vs. Signal Genetics (MGEN) - August 21 at 2:10 AM logoHead to Head Review: Signal Genetics (MGEN) and BioTelemetry (BEAT) - August 19 at 6:34 AM logoEquities Analysts Offer Predictions for BioTelemetry, Inc.'s Q3 2017 Earnings (BEAT) - August 18 at 7:20 AM logoBioTelemetry Hits a 52-Week High: What's Driving the Stock? - August 16 at 5:02 PM logoBioTelemetry Hits a 52-Week High: What's Driving the Stock? - August 16 at 5:02 PM logoEquities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2017 Earnings (NASDAQ:BEAT) - August 11 at 11:18 AM logoBioTelemetry, Inc. :BEAT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 - August 10 at 5:38 PM logoSidoti Reiterates Buy Rating for BioTelemetry, Inc. (NASDAQ:BEAT) - August 10 at 2:39 PM logoBioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates - August 9 at 4:41 PM logoEdited Transcript of BEAT earnings conference call or presentation 8-Aug-17 9:00pm GMT - August 9 at 4:41 PM logoDougherty & Co Boosts BioTelemetry, Inc. (BEAT) Price Target to $40.00 - August 9 at 1:30 PM logoBioTelemetry, Inc. Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release) - August 9 at 2:23 AM logoBioTelemetry, Inc. (NASDAQ:BEAT) Announces Quarterly Earnings Results - August 8 at 9:30 PM logoBioTelemetry posts 2Q profit - August 8 at 9:16 PM



BioTelemetry (BEAT) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.